Vitruvias Therapeutics, a specialty pharmaceutical company based in Auburn, Alabama, founded in 2013, has voluntarily recalled one lot of its Thyroid Tablets, USP 30 mg, after testing found the medication could be more potent than its label states — a defect that can push patients into hyperthyroidism, or overactive thyroid. The company announced the recall around Aug. 21-23, 2026, and the notice is also posted on the FDA (Food and Drug Administration)’s website.
Key facts
- Company: Vitruvias Therapeutics, based in Auburn, Alabama (founded 2013)
- Product: Thyroid Tablets, USP 30 mg, Lot No. 504950
- Problem: Testing found the tablets may be more potent than labeled, raising the risk of hyperthyroidism
- Distribution: Shipped nationwide from Jan. 31, 2025, to Sept. 30, 2025, to wholesalers and pharmacies
- Recall announced: Around Aug. 21-23, 2026
- Adverse events reported: Vitruvias says it has received no reports known to be related to the recall
- Company contact: safety@vitruvias.com or (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. Central time
- FDA MedWatch: 1-800-332-1088
What was recalled
The recalled batch is Lot No. 504950. Thyroid Tablets, USP is a natural, desiccated thyroid medicine made from porcine (pig) thyroid glands, containing two thyroid hormones, levothyroxine and liothyronine. It’s normally prescribed to treat hypothyroidism, an underactive thyroid — the opposite of the risk this recall raises. Vitruvias shipped the lot nationwide between Jan. 31, 2025, and Sept. 30, 2025, to the wholesalers and pharmacies it sells to directly. The recall now reaches every link after that, all the way down to bottles that may already be in a patient’s medicine cabinet.
Different from another thyroid recall
This is a separate matter from another thyroid-drug recall making news around the same time, involving Major Pharmaceuticals’ levothyroxine tablets. That recall is for a different company’s product with the opposite defect — those tablets tested too weak.
Health risks
A superpotent tablet delivers more thyroid hormone than a patient’s dose is meant to provide, which can bring on hyperthyroidism symptoms:
- Weight loss
- Heat intolerance
- Fatigue
- Nervousness
- Muscle weakness
- High blood pressure
- Chest pain
- A rapid heart rate or heart rhythm disturbances
The elderly, pregnant women and infants are at greater risk, especially with extended use — excess thyroid hormone is associated with cardiac risks in older adults, with maternal/fetal complications such as premature delivery and low birth weight in pregnancy, and with effects on growth and development in infants.
What to do if you have this medication
Vitruvias says it has not received any reports of adverse events tied to this recall so far. Anyone currently taking Thyroid, USP from Lot 504950 should not discontinue use without first contacting their healthcare provider for guidance and, if needed, a replacement prescription. Consumers with questions can reach Vitruvias Therapeutics directly at safety@vitruvias.com or (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. Central time. Anyone who experiences a problem that might be linked to this medication can also report it to the FDA’s MedWatch program at 1-800-332-1088.
Sources and further reading
- Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
- Thyroid Tablets, USP (label)
- Label: THYROID tablet
- Vitruvias Therapeutics — About
- Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency (press release)
- Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency (press release mirror)